Reading QCLS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QCLS free→Reading QCLS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QCLS free→QuarterlyIQ Insights · QCLS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On March 9, 2026, the Audit Committee of the Board of Directors (the “Committee”) of Q/C Technologies, Inc. (the “Company”) approved the dismissal of Stephano Slack LLC (“Stephano Slack”) as the Company’s independent registered public accounting firm, effective as of the same date. The reports of Stephano Slack on the Company’s consolidated financial statements for the fiscal years en…
Entry into a Material Definitive Agreement On January 16, 2026, Q/C Technologies, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Chelsea Voss (the “Consultant”), pursuant to which, the Consultant agreed to provide certain consulting services to the Company, including evaluating companies and making related introductions, analyzing technologies and operations, reviewing and advising on potential acquisitions and any other consulting or advisory servi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On January 16, 2026, the Company appointed Chelsea Voss to serve as a member of the board of directors of the Company (the “Board”). Since September 2019, Ms. Voss has served as a member of the technical staff at OpenAI where she engineers large-scale machine learning systems and works on data acquisition efforts for training artificial intelligence…
Entry into a Material Definitive Agreement On December 8, 2025, Q/C Technologies, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Ocean Avenue Holdings LLC (the “Consultant”), an entity affiliated with Martin Shkreli, pursuant to which, the Consultant agreed to provide certain consulting services to the Company, including evaluating companies and making related introductions, analyzing technologies and operations, reviewing and advising on potential…
Unregistered Sales of Equity Securities. The matters described in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 3, 2025 (the “Grant Date”), the Board of Directors (the “Board”) of the Company approved grants to each of Joshua Silverman, the Company’s Executive Chairman, Christopher Schriber, a director of the Company, Bill White, a director of the Company, Stephen Friscia, a director of the Company, Mitchell Glass, the Company’s Chief Medical Offi…
Unregistered Sales of Equity Securities. The matters described in
Entry into a Material Definitive Agreement Omnibus Waiver and Amendment As previously disclosed, on September 2, 2025, Q/C Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “Holders”) pursuant to which it agreed to sell to the Holders in a private placement (i) shares of the Company’s Series H convertible preferred stock, par value $0.001 per share, with a stated value of $1,000 per share (the “Preferred Stock”),…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 3, 2025 (the “Grant Date”), the Board of Directors (the “Board”) of the Company approved a grant to each of Joshua Silverman, the Company’s Executive Chairman, Christopher Schriber, a director of the Company, Bill White, a director of the Company, Stephen Friscia, a director of the Company, Mitchell Glass, the Company’s Chief Medical Off…
Material Modification to Rights of Security Holders The matters described in
of this Current Report on Form 8-K related to the filing of the Certificate of Amendment is incorporated herein by reference.
Material Modification to Rights of Security Holders. The matters described in
Entry into a Material Definitive Agreement As previously reported in a Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 2, 2025 (the “September 2025 Form 8-K”), on September 2, 2025, TNF Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (“Series H Purchase Agreement”) with certain accredited investors (the “Series H Investors”), pursuant to which it agreed to sell to the Series H Investors in a private placement (the “…
Termination of a Material Definitive Agreement. On September 2, 2025, the Company provided notice of its intention to terminate that certain Master Service and Technology Agreement (the “Service Agreement”), dated as of August 23, 2024, by and between the Company and Prevail InfoWorks, Inc. (“Prevail”), effective as of 30 days following such notice (the “Termination Date”). Pursuant to the Service Agreement, Prevail provided certain clinical services for the Company’s Phase 2 clinical study u…
Unregistered Sales of Equity Securities The matters described in
Material Modification to Rights of Security Holders. The matters described in Section 1.01 of this Current Report on Form 8-K related to the Certificate of Designations under the title “Preferred Stock” are incorporated herein by reference. To the extent required by
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Resignations of Jude Uzonwanne and Mitchell Glass On August 29, 2025, Jude Uzonwanne tendered his resignation as a member of the board of directors (the “Board”) of the Company and as a member of all committees of the Board on which he serves. Mr. Uzonwanne’s resignation was voluntary and not the result of any disagreement with the operations, polic…
Entry into a Material Definitive Agreement Private Placement On September 2, 2025, TNF Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 7,000 shares of the Company’s newly designated Series H convertible preferred stock, par value $0.001, with a stated value of…
Material Modification to Rights of Security Holders. To the extent required by
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 17, 2025, TNF Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the 30 consecutive business days between January 30, 2025, to March 14, 2025, the Company did not meet the…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.